Sartorius AGSARTF 84 9-Day RSI is 55.31 as of Jun. 28, 2026. GuruFocus rates SARTF with a GF Score™ of 84/100 and a GF Value™ of $234.29 (Modestly Undervalued). The stock has 9 warning signs investors should review. Among 871 Medical Devices & Instruments companies, Sartorius AG ranks worse than 74.05% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-06-28), Sartorius AG's 9-Day RSI is 55.31.
The industry rank for Sartorius AG's 9-Day RSI or its related term are showing as below:
SARTF's 9-Day RSI is ranked worse than 74.05% of 871
companies
in the Medical Devices & Instruments industry
Industry Median: 43.37
vs SARTF: 55.31
Sartorius AG (OTCPK:SARTF) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Sartorius AG 9-Day RSI Related Terms
SARTF vs ISRG, BDX, MDLN: 9-Day RSI Comparison
For the Medical Instruments & Supplies subindustry, Sartorius AG's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius AG 9-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius AG's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Sartorius AG's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius AG (SARTF) has a 9-Day RSI of 55.31 as of Jun. 28, 2026. According to the industry distribution chart, Sartorius AG ranks #645 out of 871 companies in the Medical Devices & Instruments industry, placing it in the top 74.1%.
Is Sartorius AG's 9-Day RSI too high?
Sartorius AG's current 9-Day RSI is 55.31. The Medical Devices & Instruments industry median 9-Day RSI is 43.37. Sartorius AG's value of 55.31 is 27.5% above this industry median. Based on the distribution chart, Sartorius AG ranks #645 out of 871 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Sartorius AG has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius AG's 9-Day RSI compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius AG ranks #645 out of 871 companies for 9-Day RSI. This places Sartorius AG in the lower half of its industry. The industry median 9-Day RSI is 43.37. Sartorius AG's value of 55.31 is 27.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Medical Devices & Instruments company?
The median 9-Day RSI among Medical Devices & Instruments companies is 43.37, based on 871 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius AG's current 9-Day RSI of 55.31 is 27.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median 9-Day RSI is 43.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius AG's current 9-Day RSI is 55.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius AG stock overvalued right now?
Based on GuruFocus' analysis, Sartorius AG (SARTF) is currently considered Modestly Undervalued. The stock's GF Value™ is $234.29, compared to a current price of $212.80 — trading 9.2% below its estimated fair value. The current 9-Day RSI is 55.31 and 27.5% above the Medical Devices & Instruments industry median of 43.37. Sartorius AG's overall GF Score™ is 84/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Sartorius AG (SARTF), the current 9-Day RSI is 55.31 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius AG (SARTF) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius AG stock appears to be undervalued.
The current stock price of $212.80 is trading 9.2% below its estimated GF Value™ of $234.29.
GuruFocus considers Sartorius AG to be Modestly Undervalued.
Key valuation signals for SARTF:
9-Day RSI: 55.31
GF Value™: $234.29 vs. price of $212.80 (9.2% below fair value)
Industry Position: 27.5% above the Medical Devices & Instruments median (#645 of 871)
No single metric tells the full story. See the SARTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
84GF Score
Get the complete analysis for SARTF
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SARTF has been successfully added to your 